University of Kentucky

UKnowledge
Theses and Dissertations--Public Health (M.P.H.
& Dr.P.H.)

College of Public Health

2018

Impact of Health Insurance and Sociodemographic
Characteristics on Survival for Women diagnosed with Breast
Cancer in Kentucky
Pramila Rai
University of Kentucky, pramila.rai@uky.edu

Follow this and additional works at: https://uknowledge.uky.edu/cph_etds
Part of the Public Health Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Recommended Citation
Rai, Pramila, "Impact of Health Insurance and Sociodemographic Characteristics on Survival for Women
diagnosed with Breast Cancer in Kentucky" (2018). Theses and Dissertations--Public Health (M.P.H. &
Dr.P.H.). 196.
https://uknowledge.uky.edu/cph_etds/196

This Graduate Capstone Project is brought to you for free and open access by the College of Public Health at
UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Public Health (M.P.H. & Dr.P.H.) by an
authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

STUDENT AGREEMENT:
I represent that my capstone and abstract are my original work. Proper attribution has been
given to all outside sources. I understand that I am solely responsible for obtaining any needed
copyright permissions. I have obtained needed written permission statement(s) from the
owner(s) of each third-party copyrighted matter to be included in my work, allowing electronic
distribution (if such use is not permitted by the fair use doctrine) which will be submitted to
UKnowledge as Additional File.
I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and
royalty-free license to archive and make accessible my work in whole or in part in all forms of
media, now or hereafter known. I agree that the document mentioned above may be made
available immediately for worldwide access unless an embargo applies.
I retain all other ownership rights to the copyright of my work. I also retain the right to use in
future works (such as articles or books) all or part of my work. I understand that I am free to
register the copyright to my work.
REVIEW, APPROVAL AND ACCEPTANCE
The document mentioned above has been reviewed and accepted by the student’s advisor, on
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of
the program; we verify that this is the final, approved version of the student’s capstone including
all changes required by the advisory committee. The undersigned agree to abide by the
statements above.
Pramila Rai, Student
Dr. Sarah Wackerbarth, Committee Chair
Dr. Corrine Williams, Director of Graduate Studies

Impact of Health Insurance and
Sociodemographic Characteristics on
Survival for Women diagnosed with
Breast Cancer in Kentucky
CAPSTONE PROJECT PAPER

A paper submitted in partial fulfillment of the
requirements for the degree of
Master of Public Health
in the
University of Kentucky, College of Public Health
By
Pramila Rai
Nepal

Lexington, Kentucky
04/17/2018
Capstone Committee:
Dr. Sarah Wackerbarth
Dr. Steven Fleming
Dr. Li Chen
Dr. Warren J. Christian
Dr. Moaz Abdelwadoud

1

ACKNOWLEDGEMENTS
First of all, I would like to thank my Committee Advisors Dr. Sarah Wackerbarth, Dr.
Steven Fleming, Dr. Li Chen, Dr. Warren J. Christian, and Dr. Moaz Abdelwadoud of the
University of Kentucky, without their contribution, the completion of this study would not
have been possible. It is my honor to have had faculties of their caliber shape my training
at the University of Kentucky.
I would like to thank Dr. Sarah Wackerbarth for her willingness to guide me and working
hard along with me for successful completion of this project. She helped me to overcome
all the difficulties that I faced. She encouraged me in every steps of this project. Her
constructive feedback, timely reminders are key to success of this project.
I am very much thankful to Dr. Steven Fleming for his continuous support for completion
of this project. I am gratefully indebted to his valuable inputs from the time of inception,
data collection, data analysis, report writing. He inspired me by his mind-stimulating
knowledge, experiences while I was taking his cancer epidemiology course.
I would like to extend my heartfelt gratitude to Dr. Li Chen for her guidance throughout
this project, providing me valuable feedback and for being available every time I wanted
to consult her for statistical analysis. Her input is equally unparalleled.
I would like to thank Dr. Warren J. Christian for providing highly instrumental suggestions,
and providing support throughout the process of my research project. I am also greatly
thankful for his inputs for application of GIS in this capstone project. This was not possible
without his effort.
I would like to thank Dr. Moaz Abdelwadoud for his encouragement, support, instrumental
feedback and thorough guidance for successful completion of this project.
I would also like to extend my heartfelt gratitude to Dr. Kathi Harp for her guidance in
developing proposals for this project. I would also like to thank Dr. Jaclyn K. McDowell,
an epidemiologist from Kentucky Cancer Registry for her spontaneous response and
support during data collection.
I would also like to thank the administration and staff at Kentucky Cancer Registry for
providing me requested data in timely manner, which allowed the successful completion
of this project. I would also like to thank all the faculty and staff of the College of Public

2
Health, University of Kentucky for their support in my studies.
Finally, I must express my profound gratitude to my family especially my little daughter
for keeping patience and providing me with unfailing support and continuous
encouragement throughout my years of study. This accomplishment would not have been
possible without them.
Thank you.
Pramila Rai

3

ABSTRACT
Introduction Objective of the study was to explore the impact of health insurance and
socio-demographic factors on survival for breast cancer patients in Kentucky. Breast
cancer is the most prevalent cancer among women in the US. Breast cancer survival is
affected by various factors including health insurance, residence, age, race, geographical
distance, income.
Methods The data were obtained from Kentucky Cancer Registry and included 47,128
women diagnosed with primary breast cancer between 2000 to 2014. The relationship of
health insurance and other socio-demographic factors was analyzed using Cox regression.
Results The overall five-year survival proportion was 0.97, 0.76 and 0.71 respectively for
privately insured, Medicaid and Medicare patients. Medicaid and Medicare patients had
1.89 (95% CI, 1.71-2.10), 1.96 (95% CI, 1.75-2.18) times higher hazard of dying
respectively compared to privately insured patients. Patients who had no family history of
breast cancer had a 15% (HR=1.15, p-value<0.001) higher hazard of dying compared to
those having family history of breast cancer. Tobacco use and marital status also had
significant effect on patient’s survival. Other tumor related and biological factors were also
included in the regression model. Sub group analysis by SEER summary stage also showed
that Medicaid and Medicare patients significantly at disadvantage compared to privately
insured patients for both in-situ and regional stage groups. Medicaid patients had
1.41(HR=1.41, p-value=0.0020) times higher hazard of death compared to privately
insured patients whereas Medicare patients and the privately insured patients had no
difference in hazard of death for distant stage group. Sub group analysis by age group also
showed Medicare and Medicaid patients are disadvantaged compared to privately insured
patients for all age groups.
Conclusion This study found that Medicaid and Medicare patients had higher hazard of
dying compared to privately insured patients. This helps to inform public health
professionals and policy makers for advocacy and design policies that bring equal health
outcomes regardless of insurance types.
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BACKGROUND
Breast cancer is one of the most commonly occurring cancers among women
worldwide 1 and in the United States (US).2 About one in eight women develop invasive
breast cancer over the course of their lifetime2 and an estimated 3,327,552 women were
living with breast cancer in 20143; and 236,968 women were diagnosed with breast cancer
while 41,211 women died from breast cancer in the US in the same year.4 It is estimated
that 266,120 women will be diagnosed with breast cancer in 2018. However, the relatively
higher survival probability (i.e. 89.7%) of five years or more for breast cancer patients is
positive outcome.5 Nevertheless, there is noticeable disparity in survival probability of
patients depending on the type of health insurance and other socio-demographic factors.
Health insurance is a mechanism through which a person’s health care expenses are
financed. There are different types of health insurance coverage in the US. Health insurance
policy can be broadly categorized into public and private health insurance plans, which can
further be identified into different sub-types. Public health insurance is provided with
Medicaid, Medicare and military coverage. Private health insurance is primarily provided
with employer-based insurance, followed by direct-purchase private plan.6
Health insurance has been increasingly recognized as a modifiable policy determinant
that affects the health of individuals. Studies have found that uninsured and Medicaid
insured breast cancer patients have poorer outcomes than cancer patients with private
insurance.7-11 Health insurance not only affects the survival of a patient after diagnosis, it
also affects the survival and quality of life through differential access to screening and thus
stage at diagnosis. A higher proportion of uninsured and Medicaid patients are diagnosed
with stage III and stage IV compared to privately insured patients.12 Several factors
including race, ethnicity, sociodemographic status, age, and reproductive factors affect the
incidence and the mortality pattern of breast cancer in a population.13,14 Substantial and
consistent disparities in quality of cancer care exist according to types of health insurance.
15

Race, stage at the time of diagnosis, and type of tumor also influence the survival

probability of patients. African-Americans are less likely to survive compared to other
races, an effect mediated by tumor subtypes.16
Even after many advancements in treatment and greater focus on screening, still 32%
of 5% breast cancer patients are identified respectively in regional and distant stage of
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tumors in the U.S., resulting in poor outcomes and shorter survival. In addition, breast
cancer may be characterized by different molecular subtypes with varying severity2,17,18
and survival rates, which contributes additional complexity.
Literature Review
Scientific literature was searched using databases from The National Library of
Medicine Database (PubMed) and Google Scholar with query terms, “Breast cancer
survival”, “Cancer survival” with “Disparity” “Health Insurance”, “Medicare”,
“Medicaid”, “Managed care systems”, “Private health insurance”, “Sociodemographic
status”, “Race”, “Income”.
A study conducted in metropolitan Detroit explored the relationship between race,
socioeconomic status, and breast cancer treatment and survival, and found race was not
significantly associated with survival. Low socioeconomic status, however, showed a clear
association with late-stage breast cancer at diagnosis, type of treatment received and death.
13,14

According to Surveillance, Epidemiology, and End Results (SEER) data in the 2000s,

in the white population, breast cancer incidence was 127.4 per 100,000 annually, mortality
was 12.3 per 100,000, and five-year survival was 90.4%. In the African American
population, however, incidence was 121.4 per 1000 population, mortality rate was 18.2 per
100,000, and five- year survival was 78.6%, signifying huge disparities based on
background characteristics.13
Furthermore, many studies highlighted that breast cancer survival and cancer screening
are lower when breast cancer patients had no health insurance12, 19, 20 drawing the attention
of health care professionals towards this issue. Not only the lack of health insurance, but
the type of health insurance a patient has been found to play a role. Privately insured
women have, in general, a more favorable stage of disease at breast cancer diagnosis than
do women who are insured through Medicare or Medicaid whereas uninsured women have
the least favorable outcome compared to other groups.14
A study conducted in California among the Latina ethnic group found lack of health
insurance coverage to be strongest predictor of cancer screening underutilization.19 This
gives rise to the number of women seeking health care at relatively advanced stage of the
breast cancer further leading to risk of high mortality. Similarly, a study conducted in
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Florida among female breast cancer patients diagnosed between 2007 and 2010 found that
survival was worse for uninsured patients than privately insured patients with all stages.20
In an older study conducted in 1993 by Ayanina et al., the adjusted risk of death in
breast cancer patients was 49% higher for uninsured patients and 40% higher for Medicaid
patients than for privately insured patients during the 54-89 months after diagnosis.21
In another study conducted in Kentucky the three-year relative survival proportion of
patients with breast cancer was 91% for the privately insured and 78% for uninsured
patients. This clearly indicates favorable outcome for privately insured patients. This study
also discovered the patients with Medicaid insurance had lower survival proportion
compared to privately insured patients with other cancers such as prostate cancer,
colorectal cancer and lung cancer too.22
Access to health insurance influences the frequency and quality of health care, types of
health care services and providers. Thus the insurance status of cancer patients may play
important role in their survival. A New Zealand study that included 14,468 patients, there
were differences in the characteristics of the patients themselves and the risk of mortality
depending upon the type of health care centers they utilized for the treatment. Patients,
treated in public centers, were older, belonged to minority ethnic groups, resided in poor
neighborhoods and rural areas were less likely to be diagnosed with early staged cancer
and to receive timely cancer treatments compared to women, who utilized private health
centers. They also had a higher (14% more) risk of mortality from breast cancer, even after
controlling for baseline demographic, disease and treatment factors.23 A retrospective
cohort study conducted among patients registered in the Texas cancer registry found that
those younger than 65 years without health insurance coverage had a significantly higher
risk of mortality than those with private health insurance regardless of tumor stage, and
treatment types.24 The early detection and the survival rate also varied depending on the
health care delivery systems type for patients enrolled under the same insurance program.
For this purpose, researchers studied breast care patients enrolled in Medicare, an
entitlement health insurance for older age citizen in US. The study found differential
outcomes depending on if patients were managed through Health Management
Organizations (HMOs) or the Fee for Service (FFS) system. Medicare patients enrolled in
HMOs were diagnosed at an earlier stage than FFS patients. HMO patients diagnosed with
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breast and colorectal cancer had improved survival, and these differences remained even
after controlling for potential confounders such as stage at diagnosis, age, race,
socioeconomic status, and marital status. Patients enrolled in HMOs had 9% greater
survival in hazards ratio if they had breast cancer, and 6% greater survival if they had
colorectal cancer.25 Survival probability differs between blacks and whites even if they are
diagnosed at similar stages of illness.26
Similarly, the geographic residence of the patients also affects the survival of breast
cancer patients. A study looking at the effect of distance from diagnostic hospital on
screening found that 62% of total patients with distances greater than 20 km (n=347) had
a late stage at diagnosis compared to 50% with distances less than 20 km. The risk of late
stage at diagnosis significantly increased by 1.25-fold for each 30 Km increase in
distance.27
A study by Shi et al. found that compared to white patients, black patients had a 31%
(1.31) increase, and other race had a 22% (0.78) decrease risk of death among breast cancer
patients. Patients with higher comorbidity index ≥ 2 (2.27) and 1 (1.43) Charlson
Comorbidity were more likely to die than those with no comorbid conditions.12
Other studies have also reported that insurance types, race/ethnicity, comorbidity,
geographic region or residence were associated with tumor stage at the time of diagnosis
and increased risk of deaths in breast cancer patients.16, 26,28,29 A study by Warmer et al.
found blacks had a 21% higher risk of breast cancer-specific death in multivariate adjusted
models and the survival difference was prominent in estrogen receptor-positive tumors.
Blacks were 76% and 56% more likely to die as a result of Luminal A-like and Luminal-B
like tumors respectively, compared to their white counterparts.16 Survival was primarily
different in those tumors for which survival could have been lengthened by hormonal
treatment.
Previous research has shown that survival of female breast cancer patients is affected by
numerous factors including health insurance, race, comorbidity, hormonal receptor status,
stage at the time of diagnosis, and geographical location. Patients are likely to have better
survival if they have private insurance followed by Medicare. The effect of insurance on
cancer survival in Kentucky is understudied and this present study seeks to fill that gap by
exploring the effect of health insurance for female breast cancer patients of Kentucky.
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The primary objective of the study was to evaluate the effect of health insurance types on
the survival of breast cancer patients, and type of treatment patients utilize. The secondary
objective was to assess other socio-demographic, biological factors that affect survival of
the patients.
Research Question. Do the types of health insurance affect survival of the breast cancer
patients?

METHODS
This was a retrospective cohort study which included secondary analysis of existing data
from the Kentucky Cancer Registry (KCR).
Study population. The study included women aged 19 or older with a primary diagnosis
of breast cancer registered in the KCR. There were 47,128 total patients diagnosed with
primary breast cancer from 2000 to 2015. Patients with missing information on health
insurance status and types or insurance other than Medicare and Medicaid were excluded
from the study Patients, who were in TRICARE, military personnel or their dependents
who are treated as a military facility, veterans who are treated in Veterans Affairs facilities,
Indian/Public Health service patients who receives care at an Indian Health Service facility
and costs are reimbursed by the Indian Health Service were also excluded from the study.
Hence, there were 39, 271 patients had complete information on payer status.
Data source and study population. This study included women aged 19 and older
diagnosed with primary breast cancer and registered in the Kentucky Cancer Registry from
2000 to 2015. Data was from Kentucky Cancer Registry (KCR). KCR is a statewide
population-based registry that serves as the foundation for measuring the Kentucky cancer
burden, comprehensive cancer control efforts, health disparities, progress in prevention,
diagnosis, treatment and survivorship. Data are collected for the types of cancers, disease
stage, types of first course treatment received by patients, and patient characteristics.
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Study Variables
Outcome variable
The outcome variables for this study were five-year and ten-year survival. Length of
survival was defined as time from the date of diagnosis to a 60 months and 120 months.
Independent variable
Primary independent variables. Health Insurance status of the breast cancer patients was
the primary independent variable. The health insurance status of the patients at the time of
diagnosis was be categorized into three different levels: (1) Public Health Insurance e.g.,
Medicaid and Medicare (2) Private Health Insurance; and (3) No Health Insurance.
Secondary independent variables. In addition to type of treatment, the analysis included
socio-demographic factors as well as specifics about cancer type (e.g., biological and tumor
factors).
Type of treatment
For this analysis, four categories were defined: (1) no intervention, (2) surgery at primary
site only, (3) other combination of treatment except surgery and (4) surgery at primary
site and at least other type of therapies.
Socio-demographic factors
- Appalachia: Kentucky can be divided into geographical regions of Appalachia and nonAppalachia. Appalachian region is a cultural region of Appalachia that spreads along the
spine of the Appalachian Mountains. The levels of Appalachia are residents of
Appalachia=0, residents of non-Appalachia=1.
- Race: Depending on the proportion of racial groups, the participants were categorized
into one of three categories: 0= African American, 1= Other, 2=Caucasian.
- Age of the patient at the time of diagnosis: Categorized into three groups (19-39, 40-64,
equal to or over 65 years).
- Marital status: Classified into three categories (1) single; (2) married and not living with
partners, including widowed, separated, divorced; and (3) married.
- Family history: Categorized into two groups as family history having breast cancer and
without family history of breast cancer.
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- Tobacco use: Patients were categorized based on the history of tobacco use as tobacco
user, non-user, or unknown.
Biological and tumor factors
- Surveillance, Epidemiology, and End Results (SEER) summary stage of breast cancer at
diagnosis: SEER divides the breast cancer patients based on the extent of spread of
cancer. It is defined as 1= In-situ and Localized, 2= Regional, 3= Distant.
- Estrogen Receptor (ER) and Progesterone Receptor (PR) status: Estrogen receptor status
was dichotomized into 1= ER positive (ER+) and 2= ER negative (ER-). Cases recorded
as having a borderline ER will also be classified as ER receptor-positive. Progesterone
receptor status was also dichotomized into PR positive (PR+) and PR negative (PR-).
Cases recorded as having a borderline PR status will also be classified as PR receptor- Menopausal status: Menopausal status was dichotomized into premenopausal status, and
postmenopausal status.
-Tumor grade: Tumor grade was categorized into five categories as well differentiated,
moderately differentiated, poorly differentiated, undifferentiated, non-high grade.
Data analysis
Data were analyzed using 9.4 version SAS software package. Kaplan-Meier curves and
log-rank tests were used to assess the univariate association between breast cancer patient
survival, and the types of health insurance. Impact of health insurance was further
evaluated by controlling effects of socio-demographic variables, tumor and biological
variables and health care related factors with multivariable Cox Proportional model. We
also performed sub-group analysis by SEER summary stage and age group to find the
effect of health insurance controlling effect of all other variables. We included
observations with complete information about all the covariates in multivariable Cox
regression. Multivariable Cox proportional hazards models was then used to assess the
association between breast cancer patient survival and types of health insurance adjusting
for aforementioned other factors. The backward model selection was performed.
Significance was set at p<0.05 (2-tailed). We also plotted map of counties of Kentucky
corresponding to the number of deaths due to breast cancer during our study period.
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Ethical Statement
IRB approval with an exempt application was obtained from the University of Kentucky,
Office of Research Integrity and we applied to KCR for release of data along with
application and approval letter from IRB, Kentucky Cancer Registry released the dataset
upon approval for release. However, we couldn’t obtain personal health information such
as geographical location of the patient’s residence and details about health care facilities
and providers due to nature of ethical considerations we obtained and time constraints.
KCR doesn’t collect information on education and income.

RESULTS
There were 47,128 total female patients diagnosed with primary breast cancer from
2000 to 2015. However, there were only 39,271 observations were included in the study
with complete information about the primary payer in file. Out of 39,271 patients, 11,663
had event of death.
The sample description is provided in Table 1. Comparatively higher proportion of the
patients were covered under Medicare (47.71%) followed by private (40.84%) and
Medicaid (11.45%) insurance scheme. A majority of the patients were Caucasian (92.13%)
followed by African American (7.13%) and others constituted 0.74% of the total
participants. About half (50.99%) of the patients belonged to 40-65 age category and
44.86% of the patients aged equal to or over 65 years. About a quarter (24.96%) of the total
patients belonged to Appalachian region. Majority of the participants (66.90%) were in
post-menopausal phase whereas 13.52% of the participants didn’t have any information on
menopausal status. Significant proportion of the patients (30.79%) had family history of
breast cancer. However, 22.44% of the patients didn't have any information on family
history. About half (53.14%) of the participants were married and 19.29% were widowed.
A higher percentage of patients (71.94%) had surgery at primary site and at least
another type of treatment such as chemotherapy, radiotherapy or other type of therapy. A
majority of the patients (53.24%) had localized staging of breast cancer according to SEER
summary stage followed by regional, in-situ and distant respectively. Similarly, majority
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of patients were estrogen receptor positive (71.26%) and progesterone receptor positive
(61.55%). Fewer than half (30.93%) of the breast cancer patients had poorly differentiated
tumor.
Table 1: Description of the study population from KCR, 2000 to 2015
Characteristics
Category
Frequency
Percent
Primary Payer
Medicaid
4497
11.45
Medicare
18737
47.71
Private
16037
40.84
Race
Caucasian
36182
92.35
African American
2800
7.15
Others
196
0.50
Age(years)
19-39
1629
4.15
40-64
20024
50.99
≥65
17618
44.86
Appalachia
Non-Appalachian
29469
75.04
Appalachian
9802
24.96
Marital Status at
Single
3602
9.17
Diagnosis
Married
20869
53.14
Separated
298
0.76
Divorced
4508
11.48
Widowed
7575
19.29
Unmarried or domestic
39
0.10
partner
Unknown
2380
6.06
Family History
Yes
12090
30.79
No
18366
46.77
Unknown
8814
22.44
Menopausal Status
pre-menopausal
7692
19.59
post-menopausal
26271
66.90
Unknown
5308
13.52
SEER Summary
In-situ
6225
16.01
Stage
Localized
20701
53.24
Regional
10001
25.72
Distant
1953
5.02
ER Status
Positive
27979
71.26
Negative
7275
18.53
Unknown
4012
10.22
PR Status
Positive
24170
61.55
Negative
10764
27.41
Unknown
4332
11.03
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Tumor Grade

Tobacco Use

Treatment

Well differentiated
Moderately differentiated
Poorly differentiated
Undifferentiated
Non-high grade
Never user
Cigarette smoker
Cigar/pipe smoker
Snuff/chew/smokeless
tobacco user
Mixed use of more than one
type of tobacco product
Unknown/ not recorded
No intervention
Surgery at primary site only
Surgery at Primary site and
other therapy
Other combination of
therapies other than surgery

7353
15003
12145
892
3878
19094
13331
29
47

18.72
38.20
30.93
2.27
9.87
49.04
34.24
0.07
0.12

21

0.05

6416
948
8688
28253

16.48
2.41
22.12
71.94

1382

3.52
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We also mapped the fatality rate of counties to illustrate how deaths were distributed in
Kentucky. Figure 1 shows the map of counties corresponding to hazard rate due to breast
cancer per county during the period of 2000 to 2015. The hazard of death is most
concentrated in counties in Appalachian region and western part of Kentucky.

Figure 1: Case fatality rate for breast cancer by county among women, 2000 to
2015.

Univariate effect of health insurance policy on survival for breast cancer patients
We included 39,271 patients for univariate survival analysis using log rank test and a
Kaplan Meier survival curves were produced. Out of total 4497 Medicaid enrolled women,
31.02% had event of death; out of 18,737 Medicare enrolled women, 43.81% had event of
deaths and out of 16,037 women with private insurance, 12.84 % had event of deaths (Table
2).
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Table 2: Number of events per health insurance policy
Insurance
Scheme
Medicaid
Medicare
Private
Missing and
other

Total

Death

Censored Censored %

4497
18737
16037
7857

1395
8209
2059
1895

3102
10528
13978
5962

68.98
56.19
87.16
75.88

Death %
31.02
43.81
12.84
24.12

We performed log-tank test to analyze the effect of health insurance on survival
probability of women and found significant difference in survival of women in three
different health insurance policies. Women in Medicare group had the least survival
probability whereas the women in private insurance had higher survival throughout the
follow up duration as shown in Figure 2.

Figure 2: Kaplan Meier survival curve showing survival probability in three
different insurance policy
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There was a significant difference in survival for women between every one of
insurance group with the other two groups of insurance schemes (Table 3).
Table 3: Log-rank test for multiple comparisons of health insurance groups
Adjustment for Multiple Comparisons for the
Log rank Test
Strata Comparison
payer
payer

Chi-Square

Medicaid
Medicaid
Medicare

1570.1
1918.6
3485.9

Medicare
Private
Private

p-value
Raw
<.0001
<.0001
<.0001

TukeyKramer
<.0001
<.0001
<.0001

The survival probability were 0.97, 0.76, and 0.71 for women with private, Medicaid
and Medicare respectively, at 60 months whereas the survival probability was 0.82, 0.60
and 0.48 for women with private, Medicaid and Medicare respectively, at 120 months.
There were 21,473 total cases having complete information of the variables. Among
them, 16,089 (74.93%) of the patients didn’t have event of deaths due to loss to follow up
and the study time frame, and 5384 (25.07%) patients had event of death. There were 21
parameters in the model and the number of events (5384) were enough for this
multivariable cox regression.
Multivariable effect of health insurance types on survival for breast cancer patients
Table 4 displays the results of hazard ratio (HR) of death from a multivariable cox
regression analysis. After adjusting for secondary factors, health insurance status had
significant effect for overall survival of patients. Medicare and Medicaid payer status had
significantly increased hazard of dying compared to private, with increase of 96% (HR
=1.94 p-value<.0001), 89% (HR=1.88 p-value<.0001) respectively.
There were two direct health care related factors including treatment patients utilized
and payer or health insurance status of the patients. Both factors were significantly
associated with survival of patient in the hazard model. For the purpose of regression
analysis, treatment was categorized into four different levels including a group of no
intervention, combination of therapies other than surgery at primary site, surgery at primary
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site only and the most comprehensive treatment of surgery at primary site along with at
least other treatment alternatives. Compared to women who received no intervention,
women having surgery at primary site and at least one other therapy had 0.15 (HR=0.15,
p-value<.0001) times less hazard of death. Similarly, patients who got surgery at primary
site only had significantly less hazard of death (HR=0.24, p-value<.0001) and patients who
received other combination of therapies but no surgery had 0.46 (0.46, p-value<.0001)
times less hazard of death compared to women having no intervention at all.
Similarly, other socio-demographic factors such as age, marital status, tobacco use,
family history of breast cancer were significantly associated with the hazard of death from
breast cancer. However, the geographical location of patients as Appalachia and nonAppalachia and the race of the patients didn’t have a significant relationship with the
survival of the breast cancer patients when adjusted with other covariates. Women in the
19-39 age group had a 33% (HR=0.67, p-value<.0001) decreased hazard of death
compared to women equal to or over 65 years old. Similarly, women in the 40-64 age
group had a 41% (HR=0.59, p-value<0.0001) less hazard of death compared to women in
the 65 years and older age group.
Patients with no history of tobacco use had a decreased hazard of hazard compared to
tobacco users, with a significant decrease of 24% (HR=0.76, p-value<.0001). Women
having no family history had a 15% (HR=1.15, p-value≤.0001) higher hazard of death
compared to women having family history of breast cancer. Married women or those living
with their partners had a 26% (HR =0.74, p-value<.0001) less hazard of death compared
to single women whereas women who were widowed, divorced or separated had a 17%
(HR=1.17, p-value=0.0045) higher hazard of death from breast cancer compared to single
women. Similarly, women in post-menopausal phase had a 16% (HR=1.16, p-value=
0.0041) higher hazard of death compared to pre-menopausal women even after adjusting
with other covariates.
The tumor and biological co-variates which included tumor grade, estrogen receptor
status, progesterone receptor status, SEER summary stage were also significantly
associated with survival of breast cancer patient in this cox proportional hazard model.
Patients with moderately differentiated and poorly-differentiated tumor grade had
statistically increased hazard of death with significant increase of 14% (HR=1.14, p-value
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=0.0024) and 39% (HR=1.39, p-value<0.0001) respectively. However, women with
undifferentiated and non-high grade tumor didn’t have significant effect on hazard of death.
Women with estrogen receptor negative breast cancer had a 14% (HR=1.14, pvalue=0.0032) higher hazard of death compared to women with estrogen receptor positive
breast cancer. Likewise, progesterone receptor negative breast cancer had a 25%
(HR=1.25, p-value<.0001) higher hazard of death compared to progesterone receptor
positive breast cancer. SEER summary stage also had significant impact on survival for
breast cancer patients controlling effect of other variables. Women with distant stage of
cancer had a 245% (HR=3.45, p-value<.0001) higher hazard of death whereas women with
in-situ and localized cancer had a 53% (HR=0.47, p-value <.0001) less hazard of death
respectively compared to women with regional stage of breast cancer.
Table 4: Multivariable Cox Proportional Regression: Hazard Ratio and 95%
CI of Hazard ratio per covariate
Group of
Covariates
Health care
access
covariates

Covariates
and Levels
Health
Insurance

Treatment

*SocioDemographic

Age
Appalachia
NonAppalachia
Race

Level of
Covariates

Hazard
Ratio

95% CI of
Hazard ratio
Lower
Upper
1.71
2.10

p-value

Medicaid

1.89**

Medicare
Private
Medicaid vs
Medicare
Surgery at
Primary site and
other therapy
Surgery at
Primary site
only
Other
combination of
therapies other
than surgery
No intervention
19-39
40-64
≥65
Appalachia
Non-Appalachia

1.96**
Ref.
0.97

1.75

2.18

<.0001

0.86

1.09

0.15**

0.13

0.18

<.0001

0.24**

0.20

0.29

<.0001

0.46**

0.38

0.56

<.0001

0.55
0.54

0.82
0.66

<.0001
<.0001

0.96

1.09

0.5483

AfricanAmerican
Caucasian
Others

1.71

0.91

3.20

0.0940

1.65
Ref

0.89

3.07

0.1143

Ref.
0.67**
0.59**
Ref.
1.02
Ref

<.0001
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Tobacco
use
Family
history of
breast
cancer
Marital
status

Tumor and
Biological
Characteristics

Menopausal
status

Tumor
grade

ER status
PR status
SEER
summary
stage

Never user

0.76**

0.72

0.80

<.0001

Tobacco user
No family
history

Ref.
1.15**

1.09

1.22

<.0001

Have family
history
Married

Ref.
0.74**

0.67

0.81

<.0001

Not with
partners
(widowed,
divorced,
separated)
Single
Postmenopausal
status
Pre-menopausal
status
Moderately
differentiated
Non-high grade
Poorlydifferentiated
Undifferentiated
Well
differentiated
Negative
Positive
Negative
Positive
Distant

1.17**

1.06

1.29

0.0045

Ref.
1.16**

1.05

1.28

0.0041

1.14**

1.05

1.24

0.0024

1.03
1.39**

0.91
1.27

1.16
1.52

0.6112
<.0001

0.94
Ref.

0.75

1.18

0.6060

1.14**
Ref.
1.25**
Ref.
3.45**

1.05

1.25

0.0032

1.16

1.35

<.0001

3.09

3.85

<.0001

In-situ &
localized
Regional

0.47**

0.44

0.50

<.0001

Ref.

Ref.

* KCR doesn’t collect information on Education and Income of the patients.
**significance at p-value <0.01
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Effect of health insurance types on survival for patients with subgroup analysis by
SEER summary stage
We also performed sub-group analysis by SEER summary stage in multivariable Cox
hazard model to find the effect of health insurance on survival for the patients in different
groups of SEER summary stage (Table 5).
Having private insurance is a highly protective factor for patients in all stages for
survival of the patients. Medicaid and Medicare patients had 2.13 (HR=2.13, pvalue<.0001) and 2.12 (HR=2.12, p-value<.0001) times higher hazard of death compared
to privately insured patients for in-situ and localized groups. Medicaid and Medicare
patients had 1.75 (HR=1.75, p-value<.0001) and 1.92 (HR=1.92, p-value<.0001) times
higher hazard of death compared to privately insured patients for regional stage group and
Medicaid patients had 1.41(HR=1.41, p-value=0.0020) times higher hazard of death
compared to privately insured patients whereas Medicare patients and the privately insured
patients had no difference in hazard of death for distant stage group.
Having some treatment decreased hazard of death for all stages of cancer. Surgery at
primary site and at least one other therapy had lowest hazard of death compared to surgery
at primary site only group for patients in all summary stage. Patients, who received surgery
at primary site and at least one other therapy had an 88%, 87% and 81% lower hazard of
death compared to patients who received no treatment respectively for in-situ, regional and
distant stage.
When survival rate was analyzed by stratifying the patients based on summary stage of
cancer, age had significant effect on survival for patients with in-situ and localized and
regional stage whereas the effect of age was not significant for patients with distant stage.
Patients with in-situ and localized stage in age category of 19-39 had a 59% lower hazard
of death compared to those in the 65 years or older age group.
Appalachian patients with in-situ and localized breast cancer stage had a 10%
(HR=1.10, CI=1.21-1.01) higher hazard of dying compared to non-Appalachian patients
whereas the Appalachia status had minimal effect on patients with regional and distant
stage. Marital status had significant association with survival of patients in all the stages.
Married patients had consistently lower hazard of death compared to single and the
participants not living with partners had a comparatively higher hazard of dying.
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Participants, who were not living with partners, with localized stage had a 27% (HR=1.27,
CI=1.09, 1.48) higher hazard of death compared to single participants.
Never using tobacco was a positive factor for survival for patients with localized and
regional stage whereas tobacco use was not significant for survival of patient with distant
stage. Patient who never used tobacco were 29% and 26% less likely to die compared to
patient who had history of tobacco use for localized and regional stage group respectively.
Similarly, having family history of breast cancer had a protective effect on survival for
patients diagnosed in localized and regional stage. However, family history had no
significant effect for patients with distant stage. Patients with localized breast cancer in
post-menopausal phase had a 33% greater hazard of death compared to women in premenopausal phase.
Compared to well differentiated tumor grade, patients in distant stages with moderately
differentiated tumor had a significantly (82%) higher hazard of death. Similarly, patients
with non-high grade in regional and distant stage had a 31% and 68% higher hazard of
death. Patients with poorly-differentiated tumor in localized, regional and distant stages
had a 1.28, 1.37, and 2.23 times higher hazard of death, respectively. Remarkably, patients
with localized cancer with undifferentiated tumor grade had a 24% lower hazard of death
compared to patients with well differentiated tumor grade. Negative estrogen receptor
status had increased hazard of dying in patients with regional (17%) and distant (33%)
stages whereas negative progesterone receptor status had increased hazard of death in
patients with localized (21%), regional (30%) and distant (31%) stages.
Estrogen receptor status and race had no significant effect on survival for women with
in-situ and localized summary stage patients. Appalachia, menopausal status and race had
no significant effect on survival for patients with regional summary stage. Race,
menopausal status, tobacco status, family history, Appalachia, and age had no significant
effect on survival for women with distant summary stage.
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Table 5: Effect of covariates on survival for the patients by SEER summary stage with
multivariable Cox proportional hazard model
Covariates

In-situ and Localized
Hazard
95% CI
ratio

p-value

Regional
Hazard
95% CI
ratio

p-value

Distant
Hazard
95% CI
ratio

p-value

Health Insurance
Medicaid

2.13**

1.78,2.54

<.0001

1.75**

1.50,2.03

<.0001

1.41**

1.13,1.76

0.0020

Medicare
Private

2.21**
Ref.

1.87,2.61

<.0001

1.92**
Ref.

1.61,2.29

<.0001

1.26
Ref.

0.95,1.67

0.1078

0.12**

0.09,1.17

<.0001

0.13**

0.08, 0.20

<.0001

0.19**

0.14, 0.25

0.0001

0.20**

0.15,0.27

<.0001

0.21**

0.13, 0.32

<.0001

0.45**

0.30, 0.67

<.0001

1.03

0.69,151

0.8947

0.39**

0.24, 0.63

<.0001

0.44**

0.34, 0.57

<.0001

Treatment
Surgery at primary site
and other therapy
Surgery at Primary site
only
Other combination of
therapies other than
surgery
No intervention

Ref.

Ref.

Ref.

Age
19-39
40-64
≥65

0.41**
0.49**
Ref.

0.28, 0.62
0.47, 0.57

<.0001
<.0001

0.84
0.70**
Ref.

0.64, 1.11
0.59, 0.82

0.2225
<.0001

0.68
0.77
Ref.

0.43, 1.07
0.59,1.00

0.0977
0.0524

Appalachia
Appalachia

1.10

0.99, 1.20

0.0543

0.99

0.89, 1.10

0.8427

0.95

0.80,1.12

0.5138

Non-Appalachia
Race
African American
Caucasian
Other
Tobacco use
Never user
Tobacco user
Family History
No family history
Have family history
Marital Status
Married
Not with
partners(widowed,
divorced, separated)
Single

Ref.

Ref.

Ref.

1.48
1.65
Ref

0.55, 3.99
0.62, 4.41

0.4371
0.3156

2.50
2.21
Ref.

0.80, 7.86
0.71, 6.86

0.1159
0.1721

1.00
0.93
Ref.

0.31, 3.20
0.30, 2.95

0.9998
0.9075

0.71**
Ref.

0.65, 0.76

<.0001

0.74**
Ref.

0.67, 0.81

<.0001

1.03
Ref.

0.89, 1.19

0.7111

1.14**

1.05, 1.24

0.0012

1.21**

1.10, 1.33

<.0001

1.06

0.91, 1.24

0.4487

0.62, 0.96
0.82, 1.30

0.0203
0.7831

Ref.
0.70**
1.26**

Ref.
0.60, 0.82
1.08, 1.47

<.0001
0.0034

Ref.

0.84*
1.17

Ref.
0.72, 0.99
0.99, 1.37

0.0383
0.0568

Ref.

0.77*
1.03
Ref.

Menopausal Status
Post-menopausal status
Pre-menopausal status

1.33**
Ref.

1.12, 1.58

0.0012

1.10
Ref.

0.95, 1.28

0.1985

1.02
Ref.

0.81,1.30

0.8349

Tumor Grade
Moderately differentiated
Non-high grade
Poorly-differentiated
Undifferentiated
Well differentiated

1.07
0.91
1.28**
0.74*
Ref.

0.97, 1.18
0.76, 1.08
1.14, 1.44
0.55, 0.99

0.1811
0.2698
<.0001
0.0438

1.10
1.31**
1.37*
1.67**
Ref.

0.95, 1.28
1.10, 1.56
1.07, 1.76
1.40, 2.00

0.1985
0.0029
0.0121
<.0001

1.82**
1.68**
2.23**
1.90
Ref.

1.28, 2.58
1.16, 2.43
1.56, 3.18
0.99, 3.67

0.0009
0.0058
<.0001
0.0543

1.04
Ref.

0.91, 1.19

0.5746

1.17*
Ref.

1.02, 1.34

0.0289

1.33**
Ref.

1.06, 1.66

0.0124

1.21**
Ref.

1.08, 1.35

0.0010

1.30**
Ref.

1.15, 1.48

<.0001

1.31**
Ref.

1.07, 1.61

0.0086

ER status
Negative
Positive
PR status
Negative
Positive
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*Significant at p-value<.05

**Significant at p-value<.01

Effect of health insurance types on survival for patients with subgroup analysis by
age group
We further analyzed the effect of insurance types on hazard of death by age groups
(Table 6). Of the total 1629 patients in the youngest (19-39 years) age group, 948 patients
were included in the regression analysis, 182 (19.19%) had event of death. Of the total
17,618 patients in the oldest age group ( ≥65 years), 9531 patients were included in the
regression analysis and 3527 (37%) patients had event of death. In the 40-64 age group,
(total of 20,024 patients), 10,994 were included in the regression analysis, 1675 (15.24%)
had event of death.
In this regression model, the hazard of death was significantly higher for patients with
Medicaid and Medicare compared to women with private insurance in the (18-39)-year age
group and 40-65 age group. However, for patients over or equal to 65-year age group, there
was no significant difference in hazard of death between patients enrolled in private and in
Medicaid insurance.
In the 19-39 age group, the hazard of death is 84% and 116% higher for patients
enrolled in Medicaid, Medicare respectively compared to patients with private insurance.
Appalachia, race, family history, tobacco status, marital status, menopausal status, estrogen
receptor status, progesterone receptor status, and weren’t associated with the survival of
women in the 19-39 age group.
The hazard of death was significantly higher for patients with Medicaid and Medicare
insurance compared to women with private insurance in 40-64 age group with increased
hazard of 91% and 127% respectively. Appalachia and race weren’t associated with
survival of patients in the 40-64 age group.
Patients enrolled in Medicare had significantly (45%) higher hazard of death compared
to women with private insurance in the 65 years or older age group. Appalachia,
menopausal status, race, and estrogen receptor status had no significant impact on survival
for patients 65 years or older (Table 6).
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Table 6: Effect of Covariates on Survival for breast cancer patients by Age groups with
Multivariable Cox Proportional Hazard Model
Covariates

19-39 years
Hazard
CI
ratio

p-value

40-64 years
Hazard
CI
Ratio

p-value

≥65 years
Hazard
CI
ratio

p-value

Health Insurance
Medicaid

1.84**

1.31, 2.60

0.0005

1.91**

1.69, 2.15

<.0001

1.30

0.89,1.89

0.1820

Medicare
Private

2.16*
Ref.

1.05, 4.44

0.0352

2.27**
Ref.

1.97, 2.60

<.0001

1.45**
Ref.

1.20, 1.75

0.0001

27343.95

0,1.25E298

0.9764

0.12**

0.08, 0.18

<.0001

0.14**

0.11,0.17

<.0001

21140.69

0, 9.66E297

0.9770

0.15**

0.10, 0.22

<.0001

0.23**

0.19, 0.29

<.0001

151479.6

0, 6.92E298

0.9724

0.30**

0.20, 0.46

<.0001

0.45**

0.36, 0.56

<.0001

Treatment
Surgery at Primary site
and other therapy
Surgery at Primary site
only
Other combination of
therapies other than
surgery
No intervention

Ref.

Ref.

Ref.

Appalachia
Appalachia
Non-Appalachia

1.32
Ref.

0.92, 1.89

0.1274

1.04
Ref.

0.93, 1.17

0.4624

0.99
Ref.

0.92, 1.08

0.8787

Race
African American
Caucasian
Other

1.66
1.02
Ref.

0.39, 7.07
0.25, 4.23

0.4954
0.9738

2.06
2.10
Ref.

0.76, 5.56
0.78, 5.61

0.1550
0.1398

1.69
1.66
Ref.

0.63, 4.55
0.62, 4.44

0.2998
0.3115

Tobacco Use
Never user
Tobacco user

0.72*
Ref.

0.52, 0.99

0.0448

0.70**
Ref.

0.64, 0.78

<.0001

0.78**
Ref.

0.73, 0.84

<.0001

Family History
No family history
Have family history

0.88
Ref.

0.65, 1.19

0.4149

1.19**
Ref.

1.07, 1.31

0.0008

1.16**
Ref.

1.08, 1.24

<.0001

0.84
0.99

0.58, 1.22
0.62, 1.59

0.3578
0.9870

0.86
1.15

0.74, 1.01
0.98, 1.34

0.0588
0.0954

0.67**
1.15

0.58, 0.77
0.99, 1.31

<.0001
0.0515

Marital Status
Married
Not with
partners(widowed,
divorced, separated)
Single

Ref.

Ref.

Ref.

Menopausal Status
Post-menopausal status
Pre-menopausal status

1.32
Ref

0.76, 2.28

0.3243

1.15**
Ref

1.03,1.27

0.0109

0.91
Ref

0.49, 1.69

0.7550

Tumor Grade
Moderately differentiated

1.66

0.65, 4.25

0.2914

1.29**

1.08, 1.54

0.0039

1.11*

1.01,1.22

0.0280

Non-high grade
Poorly-differentiated

2.12
2.44

0.69, 6.52
0.96, 6.20

0.1881
0.0615

1.13
1.58**

0.89, 1.43
1.32, 1.89

0.3095
<.0001

1.02
1.36**

0.88,1.17
1.22, 1.51

0.8133
<.0001

Undifferentiated
Well differentiated

4.16*
Ref.

1.16,14.86

0.0284

1.10
Ref.

0.73, 1.66

0.6495

0.87
Ref.

0.65,1.16

0.3445

1.10
Ref.

0.68, 1.77

0.7062

1.25**
Ref.

1.07, 1.45

0.0045

1.08
Ref.

0.96,1.20

0.1999

ER status
Negative
Positive
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PR status
Negative
Positive

1.18
Ref.

0.73, 1.90

0.4958

1.38**
Ref.

1.20, 1.59

<.0001

1.20**
Ref.

1.09, 1.32

0.0001

2.06*

1.09, 3.90

0.0260

4.27**

3.61, 5.05

<.0001

3.02**

2.60,3.51

<.0001

Localized
0.23**
0.15, 0.35
<.0001
Regional
Ref.
*Significant at p-value<0.05 **Significant at p-value<0.01

0.35**
Ref.

0.31, 0.39

<.0001

0.56**
Ref.

0.52,0.60

<.0001

SEER stage
Distant

DISCUSSION
The purpose of this study was to evaluate the effect of types of health insurance and
other socio-demographic factors on survival for women with breast cancer. We included
women with breast cancer to understand their survival based on their health insurance types
and other covariates. We found that the survival is highest among patients with private
insurance while the patients with Medicaid and Medicare had comparatively lower survival
probability post-diagnosis. Effect of health insurance on hazard of death was still present
even after controlling other socio-demographic factors, tumor and biological
characteristics and treatment factors in the regression model. The hazard ratio was higher
for Medicare patients (94% vs 88%) than Medicaid patients compared to patients with
private health insurance. Previous studies have shown that uninsured and Medicaid
enrolled patients are at increased hazard of death compared to privately insured breast
cancer patients. A study by Gorey et. al. (2011) using a California population and another
study using data from Texas Cancer Registry by Zhang et.al. (2015) concluded that
privately insured women were at an advantage on survival compared to the uninsured or
those insured by Medicaid.11, 24 Other studies have focused on the differential effect on
survival due to private and Medicaid insurance. However, Medicare patients are also
significantly disadvantaged for survival compared to patients with private health insurance
as depicted in this study.
When multivariable Cox regression was performed to evaluate effect of health
insurance controlling effects of other covariates by age group, the hazard was insignificant
between patients with Medicaid and private insurance in older than 65-year age group.
However, the hazard of death was significantly higher (45%) for patients with Medicare
compared to patients with private insurance. Even though some other socio-demographic
factors, tumor and biological factors lost their significance in the multivariable model,
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health insurance and treatment type remained consistently significant in the model in all
age groups. These findings highlight the importance of these health care factors in affecting
survival of the breast cancer patients.
A study by Shi et al (2013) found the survival outcome was different for patients
enrolled in Medicaid and private health insurance even when patients got the same type of
treatment administered by the clinicians in a public hospital.30 This differential outcome
could be attributed to the fact that patients without private health insurance are diagnosed
in the later stage of disease. The relationship of personal characteristics of the patient and
the enrollment in the health insurance policy should also be taken into consideration.
Some studies also implied differential quality of treatment rendered to patients
depending upon their insurance coverage. A study done by Parikh-Patel et al. found that
breast cancer patients in all other insurance groups including Medicare, Medicaid,
uninsured group had significant lower odds (16-25%) of receiving radiation after breast
conserving surgery (BCS) compared with the privately insured group.15 Similarly, for
patients with four or more positive lymph nodes, uninsured and dual eligible patients had
significantly lower odds of receiving radiation therapy after mastectomy.15 This finding
was further supported by other studies conducted to assess impact of insurance types on
the treatment pattern among breast cancer patients.30-34 Another study conducted in Florida
by Voti et al. found that women with Medicaid at the time of diagnosis were 29% less
likely to receive recommended treatment for breast cancer compared to patients with
private insurance.35 Those finding suggest role of insurance in determining quality of health
care they received and these findings should be taken into account while deciphering the
mechanism by which health insurance affect the survival of the patients.
Even within insurance types, differences in outcomes have been seen in patients in
capitated and fee-for-service systems. A study by Kirsner et al., found that 13.1% of HMO
patients were diagnosed in an in-situ stage compared with 10.8% of FFS patients for breast
cancer.25 Similarly, Medicare patients enrolled in HMO healthcare delivery systems had
greater survival when diagnosed with breast cancer, either as a first cancer diagnosis or
subsequent cancer diagnosis compared with patients enrolled in FFS systems.29 The
differences remained even after controlling for potential confounders.
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One study hypothesized Medicaid patients would have a higher likelihood of late-stage
disease at diagnosis and a lower likelihood of receiving radiation therapy compared to
women not insured by Medicaid. The difference being due to circumstances beyond the
control of insurance status as such patients insured by Medicaid may have comorbid
conditions that interfere with cancer screening and treatment and physicians may be
reluctant to recommend routine screening or cancer treatment for low-income women, even
those who are insured.14
The effect of geographical distribution of the patients did not have any significant effect
on survival of the patients though Appalachian patients had significantly higher hazard
ratio compared to non-Appalachian patients in univariate Cox regression. Being married
or living with partners were found to be a protective factor for survival of breast cancer
patients. This finding could be related to the fact that having partner shortens the delay in
seeking health care as was found in a population-based study done using register-sampled
cancer patients in the Aarhus County, Denmark implying partner support to be significantly
associated with shorter patient delay in health seeking among cancer patients.36 Partner
support explains one way of advantage being in relationship at the time of diagnosis and
subsequent care of breast cancer patients.
Conclusion and Limitation
This study is based on secondary data analysis of breast cancer patients to determine the
impact of health insurance on survival of breast cancer patients. This research project also
depends on the only available structured information that limits potential of the researcher
and the project to explore in depth mechanism by which health insurance affects survival.
Original research with primary data could answer several questions about the quality and
accessibility of health care services by the breast cancer patients. Health insurance ensures
the access of health care when needed. Hence, including components of health care access
such as appointments to care providers, type of health care providers, and treatment as
intermediary model could be more useful to understand the pathways of disparities in
survival probability due to health insurance. Lack of information about education and
income might also affect the overall impact of health insurance on survival as their effect
are not controlled in the regression model.
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This issue has attained considerable attention from the government and other medical
professionals and allied health care organizations. In the meantime, assessing the effect of
health insurance on breast cancer patients underlines its importance in improving survival,
and helps demonstrate the disparities in survival rates of breast cancer patients, as well as
provides evidence regarding the discrepancy of health insurance types and their effects.
Given the high burden and mortality of breast cancer among US women, this should be
high priority among policymakers and health care professionals to ensure the availability
and affordability of health care when needed to decrease the mortality and to increase the
quality of life among survivors.
This study shows a higher hazard of death in patients with Medicaid and Medicare
compared to privately insured patients requiring an action to understand thoroughly how
they are varied. This study also validates health insurance as an imperative modifiable
factor of survival of breast cancer patients. Health insurance has been highly debated policy
issues of US health care system and with expansion of Medicaid, it is pushed as right of
every individual. However, our research supports that having health insurance is not
sufficient enough, policy makers should be aware about how quality of health care and
health outcome are affected by health insurance policies. It is highly recommended to
ensure that those insurance policies provide at least the same basic level of coverage that
brings equal health outcome for the disease.
Recommendations
A detailed study to find out the financing detail in each insurance policy for treatment of
breast cancer is recommended to understand any factors motivating care provider’s
behavior. Further study detailing physician perspectives on how they recommend treatment
and their perception about consideration of insurance while recommending treatment and
patients perspectives on how they are recommended treatment based on insurance could
help in understanding impact of health insurance in real life scenario. Hence, large scale
original research projects could be performed to extract views and perceptions of those
patients covered with different insurance types. Policy analysis of health insurance
organizations regarding coverage of breast cancer patients can be carried out to understand
policies of health insurance companies.
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In conclusion, the findings from this study can help to inform public health
professionals and policy makers about impact of health insurance on survival of female
breast cancer patients and help to design policies that reduce disparity in health outcome
depending on types of health insurance. Improving provision of health care services under
Medicare and Medicaid may improve breast cancer outcomes.
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